Advertisement
Screener

Lucid Diagnostics Inc. (LUCD) Increase (Decrease) in Accounts Receivable

2.8 / 5 stars · 68/120 Roast Me

Lucid Diagnostics Inc. Increase (Decrease) in Accounts Receivable

Lucid Diagnostics Inc. (LUCD) reported Increase (Decrease) in Accounts Receivable of $445.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-12

  • Lucid Diagnostics Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $399.00K, a 27.88% increase year-over-year.
  • Lucid Diagnostics Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $46.00K, a 187.50% increase year-over-year.
  • Lucid Diagnostics Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $96.00K, a 1271.43% increase year-over-year.
  • Lucid Diagnostics Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $177.00K.
  • Lucid Diagnostics Inc. increase (decrease) in accounts receivable for fiscal 2025 was $601.00K.
  • Lucid Diagnostics Inc. increase (decrease) in accounts receivable for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
  • Lucid Diagnostics Inc. increase (decrease) in accounts receivable for fiscal 2023 was $28.00K.
  • Lucid Diagnostics Inc. increase (decrease) in accounts receivable for fiscal 2022 was -$183.00K, a 191.50% decline from fiscal 2021.
Period endIncrease (Decrease) in Accounts Receivable 3 monthIncrease (Decrease) in Accounts Receivable 6 monthIncrease (Decrease) in Accounts Receivable 9 monthIncrease (Decrease) in Accounts Receivable 12 month
2026-06-30$399.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
$445.00K
10-Q · filed 2026-08-12
$541.00K
derived: sum of 3 quarters · filed 2026-08-12
$718.00K
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31$46.00K
10-Q · filed 2026-05-13
$142.00K
derived: sum of 2 quarters · filed 2026-05-13
$319.00K
derived: sum of 3 quarters · filed 2026-05-13
$631.00K
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31$96.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
$273.00K
derived: sum of 2 quarters · filed 2026-03-25
$585.00K
derived: sum of 3 quarters · filed 2026-08-12
$601.00K
10-K · filed 2026-03-25
2025-09-30$177.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$489.00K
derived: sum of 2 quarters · filed 2026-08-12
$505.00K
10-Q · filed 2025-11-12
$512.00K
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30$312.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
$328.00K
10-Q · filed 2026-08-12
$335.00K
derived: sum of 3 quarters · filed 2026-08-12
$213.00K
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31$16.00K
10-Q · filed 2026-05-13
$23.00K
derived: sum of 2 quarters · filed 2026-05-13
-$99.00K
derived: sum of 3 quarters · filed 2026-05-13
$12.00K
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$7.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
-$115.00K
derived: sum of 2 quarters · filed 2026-03-25
-$4.00K
derived: sum of 3 quarters · filed 2026-03-25
$0.00
10-K · filed 2026-03-25
2024-09-30-$122.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
-$11.00K
derived: sum of 2 quarters · filed 2025-11-12
-$7.00K
10-Q · filed 2025-11-12
$17.00K
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30$111.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
$115.00K
10-Q · filed 2025-08-12
$139.00K
derived: sum of 3 quarters · filed 2025-08-12
$125.00K
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31$4.00K
10-Q · filed 2025-05-13
$28.00K
derived: sum of 2 quarters · filed 2025-05-13
$14.00K
derived: sum of 3 quarters · filed 2025-05-13
$22.00K
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31$24.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24
$10.00K
derived: sum of 2 quarters · filed 2025-03-24
$18.00K
derived: sum of 3 quarters · filed 2025-03-24
$28.00K
10-K · filed 2025-03-24
2023-09-30-$14.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
-$6.00K
derived: sum of 2 quarters · filed 2024-11-12
$4.00K
10-Q · filed 2024-11-12
-$10.00K
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$8.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12
$18.00K
10-Q · filed 2024-08-12
$4.00K
derived: sum of 3 quarters · filed 2024-08-12
$35.00K
derived: sum of 4 quarters · filed 2024-08-12
2023-03-31$10.00K
10-Q · filed 2024-05-13
-$4.00K
derived: sum of 2 quarters · filed 2024-05-13
$27.00K
derived: sum of 3 quarters · filed 2024-05-13
-$62.00K
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31-$14.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25
$17.00K
derived: sum of 2 quarters · filed 2024-03-25
-$72.00K
derived: sum of 3 quarters · filed 2024-03-25
-$183.00K
10-K · filed 2024-03-25
2022-09-30$31.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
-$58.00K
derived: sum of 2 quarters · filed 2023-11-13
-$169.00K
10-Q · filed 2023-11-13
-$169.00K
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30-$89.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14
-$200.00K
10-Q · filed 2023-08-14
-$200.00K
derived: sum of 3 quarters · filed 2023-08-14
2022-03-31-$111.00K
10-Q · filed 2023-05-15
-$111.00K
derived: sum of 2 quarters · filed 2023-05-15
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14
$200.00K
10-K · filed 2023-03-14
2021-09-30$200.00K
10-Q · filed 2022-11-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
KORU Medical Systems, Inc. (KRMD)United States$0.151B-106.78
Profound Medical Corp. (PROF)$0.206B-7.37
Neuronetics, Inc. (STIM)United States$0.216B-3.25
Apyx Medical Corp (APYX)United States$0.120B-21.85
PRO DEX INC (PDEX)United States$0.234B13.64
UTAH MEDICAL PRODUCTS INC (UTMD)United States$0.238B20.93
Microbot Medical Inc. (MBOT)$0.089B-7.97
LENSAR, Inc. (LNSR)United States$0.087B2.02
InfuSystem Holdings, Inc (INFU)United States$0.253B22.52
SkinHealth Systems Inc. (SKIN)United States$0.086B-3.17